Enter assignee name

% Expired Patents = 63.6

Forward Citations = 35

Loading Chart...

6 inventors (with patents filed for the assignee):

David Erick Wright (7 out of 16 patents)

John S O'Brien (5 out of 11 patents)

D Elliott Parks (5 out of 5 patents)

4. Yasuo Kishimoto (4 out of 6 patents)

5. D Elliot Parks (1 out of 11 patents)

6. Michael T White (1 out of 1 patent)

11 patents: Sort by Forward Citations

1. 8063016 - Retro-inverso peptides derived from interleukin-6 (2011-11-22),

2. 7754690 - Method of using retro inverso peptides derived from leukemia inhibitory factor (2010-07-13),

3. 7754688 - Methods of using retro-inverso peptides derived from interleukin-6 (2010-07-13),

4. 7524818 - Prosaposin as a neurotrophic factor (2009-04-28),

5. 7135461 - Retro-inverso peptides derived from interleukin-6 (2006-11-14),

6. 7115571 - Retro-inverso peptides derived from interleukin-3 (2006-10-03),

7. 7109168 - Retro-inverso peptides derived from leukemia inhibitory factor (2006-09-19),

8. 6590074 - Prosaposin receptor (2003-07-08),

9. 6559124 - Use of prosaposin and peptides obtained therefrom for treatment of neural degeneration (2003-05-06),

10. 6458357 - Retro-inverso neurotrophic and analgesic peptides (2002-10-01),

11. 5571787 - Prosaposin as a neurotrophic factor (1996-11-05),

Myelos Corporation is a leading biotechnology company dedicated to innovating advanced therapies for hematologic disorders. With a focus on developing novel treatments for diseases such as sickle cell anemia and leukemia, Myelos is committed to improving the quality of life for patients around the world. By leveraging cutting-edge research and technology, Myelos aims to revolutionize the field of hematology and make a lasting impact on global health.

This text is generated by artificial intelligence and may not be accurate.